Pfizer reported Q4 2024 revenue of $17.8 billion, with $13.7 billion from non-COVID products, reflecting 11% operational year-over-year growth. Key growth drivers included the Vyndaqel family ...

Demand for Pfizer’s COVID-19 products and oncology drugs could fall short of expectations, and risks related to key product sales, pricing pressure, and pipeline developments persist.